Antibody Optimization
RevoAb™ solves
the toughest antibody challenges—
Beyond trial-and error
-
Difficult-to-Express
-
Difficult-to
-Concentrate -
Difficult-to-Store
About
Get the Winning
Antibody
Sequences
Instantly Online
Service Introduction Video (2 min)
Rather than wasting time on random screening, our proprietary database(patent pending) enables the rapid design of sequences with a high probability of success in boosting expression and stability- delivered within 2 weeks.
This removes bottlenecks from your research and development process.
Three reasons to Choose RevoAb™
Design Rationale to Identify the Winning Antibody Sequences
Leveraging RevolKa’s proprietary sequence design technology, “Naturalness Design™” (patent pending), we identify three “winning sequences” with the highest probability of enhancing antibody properties- selected from a vast natural antibody framework database of 1066 possible sequences – and deliver them directly to you!
CDRs Intact-Focus Exclusively on Frameworks
At RevoAb™, we leave your critical Complementary-Determining Regions(CDRs) untouched, focusing solely on framework engineering to boost developability properties.
Your CDR sequences can remain undisclosed, ensuring full research confidentiality.
No More Bottlenecks
We deliver optimized sequences within just two weeks of your request,
helping accelerate your research and development.
- 1 Online ApplicationSubmit your antibody sequence information(CDRs are optional) via the form.
- Payment within 2 weeks
- 2 Delivery of ResultsWe provide three winning sequences as text data.
Case Study
Dramatically Improve
Expression Levels
- Targets: An independent difficult-to-express antibody
- Results: Identified variants of the difficult-to-express single-chain variable fragments (scFvs), showed dramatic increases in yields in E.coli. The Tm value increased by more than 5 °C when compared among the expressed variants, while the wild-type could not be expressed for comparison. Also, the binding affinities to the antigen of the the RevoAb™ variants were comparable to that of the wild-type(WT).
8 out of 8 projects showed improvement
Results are from internal studies, do not guarantee success
To Whom, For What?
-
Challenges with antibody stability
Great affinity and pharmacological effects, but poor developability due to aggregation issues
Researchers in Pharma & Biotech
-
Challenges with Antibody yields
Large-scale expression required for further studies, such as in vivo experiments, due to ultra low yields
Researchers in Academia
-
Challenges with manufacturing costs
Need to reduce manufacturing costs for diagnostic kits to improve market competitiveness
Researchers in Diagnostics
Pricing
Budget-friendly Prices
-
Fragment of variable regions (Fv)¹⁾
Human, Rabbit, Mouse, Rat origins
$ 700
-
Fragment of variable regions (Fv)¹⁾
Other origins
$ 350
-
Variable heavy domain of heavy chain (VHH)²⁾
Camelids origins
$ 350
- 1) One target: one heavy chain sequence + one light chain sequence. Humanized Fv is considered as human.
- 2) Humanaized VHH is not supported.
* Cancelation policy: No cancellations and refund after registration
Discounts
- 10% discount for returning customers
- 10% discount on the full-package service, aiProtein, to RevoAb™ customers
Are my antibodies the target?
If you're concerned, contact us now!
Antibody
Support for Various
Antibody Formats
- IgG
- scFv
- VHHExcluding humanized
antibodies
* As of September 2025, bispecific antibodies are not supported, but support is planned for future updates.
FAQ
q. Is Fc covered?
No, it is not covered by the RevoAb™ online service. It may be covered by the full-package service, aiProtein. Please feel free to contact us.
q. Will this service propse three winning-sequences with potential improvement in general physicochemical properties?
Yes, RevoAb™ is a online service that propose three candidate sequences with potential improvement in general properties. This means that RevoAb™ does not gurantee improvement in a particular property.
If your antibody has challenges with a particular property, we recommend the full-package service, aiProtein. We are happy to consult- Please feel free to contact us.
q. Can I specify properties I would like to improve?
No, you cannnot specify a particular property in the RevoAb™ service. RevoAb™ proposes three variant sequences with potential improvement in general physicochemical proteries, such as expression levels, stability, etc.
The full-package service, aiProtein, offers a customized engineering, where customers can specifiy particular properties of interest. Sequences from RevoAb™ are going to be utilized for machine-learning in aiProtein service. RevoAb™ customers are eligible for various discounts. We recommend aiProtein service especially if you see improvement in your properties of interest with the sequence from RevoAb™. We are happy to consult- Please feel free to contact us.
q. Will the winning sequences be experimentally validated for properties?
No, RevoAb™ will not provide experimental validation data. This service proposes antibody sequences with potential improvement physicochemical properties, such as expression levels, stability, etc.
We plan to include simple validation experiments in the future. Please stay tuned for updates!
q. Do I need to submit any data regarding a property of interest?
No, this service does not require you to submit any experimental data about properties of interest. For your information, if you want to optimize specific properties or balance multiple properties, we recommend the full-package machine-learning service, aiProtein. We are happy to consult- Please feel free to contact us.
q. How many variant sequences will be proposed?
Three sequences each for heavy and light chains. Depending on the sequence, fewer than three may be proposed.
q. Is a bispecific antibody covered by this service? If yes, is a bispecific antibody counted as one target?
No, the current version (September 2025 release) does not support bispecific antibodies. For now, we propose optimization of the antigen binding fragment for each antigen individually.
Support for bispecific antibodies is planned for release in April 2026. Please stay tuned for updates!
q. Is a difficult-to-express protein covered by this service? Does our protein need to have some expression to start with?
Yes, difficult-to-express proteins are fully covered. Both RevoAb™ and the full-package service aiProtein have extensive experience in improving expression levels. Please feel free to contact us!
q. I worry about increased immunogenicity due to mutations introduced in this service, especially for therapeutic antibodies.
We understand your concern. We apply Naturalness Design, which makes antibody framework sequences closer to naturally occuring ones. This approach helps reduce the risk of immunogenicity. However, we recommend evaluating immunogenicity risks of proposed sequences by in silico or lab-based immunogenicity tests.
q. Is a humanized mouse antibody treated as a mouse or human antibody?
Humanized Fv is considered as human.
q. Do we need to upload full-length sequences of IgG, including constant regions?
No, you don't, Only variable region squences (VH+VL) are required. For your information, CDR sequences are optional.
q. Is there anything I need to take care when I start a business with an anitibody proposed by this service?
The rights to sequences proposed in RevoAb™ service belong to the user, while granting a free license to us for internal use. There are no restrictions on engineering, joint research, or commercialization.
q. Who owns the deliverable sequences?
They belong to the user.
q. Can I ask about data security at RevolKa?
This service is provided under the “Terms of Use” and the “Consent to Personal Information Handling.” Regarding confidentiality, please review Section 7 in the “Terms of Use” .
q. The Terms of Use says, "The User agrees to grant the Company the right to use such content freely, without compensation and without limitation, for any purpose.". What does this "any purpose" mean?
Thank you for asking this important question. We will not use any information, including user provided sequences and result sequences, only for internal purposes, such as improving the quality of service. All of the information will be hundled in sccordance with Section 7 "Confidentiality" of the "Terms of Use"
Full Package Service
To All Antibody innovators
RevoAb™ + aiProtein®: A Complete Antibody Optimization Pipeline
RevoAb™ identifies the candidate mutations, then aiProtein®'s AI finds the perfect combinations for next-level antibody performance!
aiProtein® is offered in collaboration with FUJIFILM Wako Chemicals Europe, GmbH
